Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $266.00 at Citigroup

Posted by Defense World Staff on Aug 6th, 2023

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective increased by investment analysts at Citigroup from $265.00 to $266.00 in a report released on Friday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 43.33% from the stock’s current price.

A number of other brokerages have also commented on ALNY. Sanford C. Bernstein decreased their price objective on Alnylam Pharmaceuticals from $247.00 to $233.00 in a research report on Wednesday, July 26th. HC Wainwright reduced their target price on Alnylam Pharmaceuticals from $415.00 to $405.00 and set a “buy” rating for the company in a report on Tuesday, July 25th. Sumitomo Mitsui Financial Group started coverage on Alnylam Pharmaceuticals in a report on Wednesday, April 26th. They issued a “neutral” rating and a $220.00 target price for the company. BMO Capital Markets raised Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $200.00 to $250.00 in a research report on Friday, May 5th. Finally, Royal Bank of Canada dropped their price target on Alnylam Pharmaceuticals from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 25th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $251.05.

Alnylam Pharmaceuticals Trading Down 2.4 %

Shares of ALNY opened at $185.58 on Friday. The business’s 50-day moving average price is $195.05 and its 200 day moving average price is $201.20. The stock has a market capitalization of $23.11 billion, a P/E ratio of -21.55 and a beta of 0.49. Alnylam Pharmaceuticals has a 1-year low of $179.19 and a 1-year high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57. The firm had revenue of $319.29 million for the quarter, compared to analysts’ expectations of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 85.95%. Alnylam Pharmaceuticals’s revenue was up 49.7% on a year-over-year basis. During the same quarter last year, the business posted ($2.00) EPS. On average, research analysts predict that Alnylam Pharmaceuticals will post -6.45 earnings per share for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Belpointe Asset Management LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth $25,000. ANTIPODES PARTNERS Ltd acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth $28,000. Capital Advisors Ltd. LLC boosted its stake in Alnylam Pharmaceuticals by 1,480.0% in the second quarter. Capital Advisors Ltd. LLC now owns 158 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 148 shares in the last quarter. KB Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals in the first quarter worth $35,000. Finally, Archer Investment Corp acquired a new position in Alnylam Pharmaceuticals in the first quarter worth $40,000. Institutional investors and hedge funds own 94.43% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.